


**IN THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-34. (Canceled)

35. (Currently Amended) A method of inhibiting HIV replication, said method comprising contacting a cell comprising HIV with an effective amount of a compound having the structure:



wherein


A is selected from the group consisting of N, CR<sub>1</sub>, and  $\begin{array}{c} \text{R}_1 \\ | \\ \text{---CHN---} \end{array}$ ;

B is selected from the group consisting of N and S;

Y is selected from the group consisting of Se, CH and CR<sub>4</sub>;


X is selected from the group consisting of CH and N;

R<sub>1</sub> is selected from the group consisting of H, NR<sub>5</sub>R<sub>6</sub> and




R<sub>2</sub> and R<sub>3</sub> are independently selected from the group consisting of H, halo, hydroxy and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sub>4</sub> is selected from the group consisting of H, halo, hydroxy and C<sub>1</sub>-C<sub>4</sub> alkyl;



R<sub>5</sub> and R<sub>6</sub> are independently selected from the group consisting of H and C<sub>1</sub>-C<sub>4</sub> alkyl;


R<sub>7</sub> and R<sub>8</sub> are independently selected from the group consisting of H, halo, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, -NHC(O)CH<sub>3</sub> and -O(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>5</sub>-C<sub>6</sub> heterocyclic) or R<sub>7</sub> and R<sub>8</sub> together with the atoms to which they are attached form an optionally substituted C<sub>5</sub>-C<sub>6</sub> aryl, wherein the aryl ring is optionally substituted with halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkyl(C<sub>5</sub>-C<sub>6</sub> aryl) and -O(C<sub>1</sub>-C<sub>4</sub> alkyl)(C<sub>5</sub>-C<sub>6</sub> heterocyclic). In one embodiment Y is CR<sub>4</sub>, R<sub>7</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkoxy, R<sub>8</sub> is halo or



independently selected from the group consisting of O, S, CH<sub>2</sub> and NH;


further wherein said compound is selected from the group consisting of

103833:




3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide,

AE-641/15124054 (311)




AE-848/11105217 (312)



(313)


~~AE-848/34405027~~



5

(314)


AG-205/08592044



,


(315)

AG-205/11781740




,

~~AG-205/31312022~~ (316)




5

~~AG-205/33137032~~ (317)




5

AG-205/33137032 (318)




5

~~AG-205/33139015~~ (319)




5

AG-205/33156001 (320)




5

AG-205/33684025 (321)




5


~~AG-205/36992106~~ (322)




AG-690/1370414 (323)




AG-690/34037018 (324)




AH-262/343350 (325)



AH-262/36083007 (326)




AK-777/115000 (327)







AK-777/36935027 (328)




AK-968/37156085 (329)



AM-807/12740245 (330)




~~AM-807/13614287~~ (334)




5

~~AM-807/14147906~~ (332)




5

~~AM-807/42004022~~ (333)




5


AM-807/42860050 (334)




AN-329/05740035 (335)




AN-919/14791006 (336)



AO-799/42008042 (337)




AO-799/43115183 (338)



and

(339)


AQ-750/42052143



36. (Previously Presented) The method of claim 35, wherein said compound inhibits REV function.

37. (Previously Presented) The method of claim 35, wherein HIV virion production is dependent on Rev protein expression.

38. (Previously Presented) The method of claim 35, wherein said compound is 103833:



3-amino-5-ethyl-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide